| Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates |
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for the first quarter ended March 31, 2025. “In the first quarter of 2025, we continued to make progress with our pipeline programs by exercising our option early to license VS-7375 from our partner GenFleet Therapeutics, completing enrollment in the initial c. |
businesswire.com |
2025-05-13 20:34:00 |
Czytaj oryginał (ang.) |
| FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer |
BOSTON--(BUSINESS WIRE)---- $VSTM #FDA--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has approved AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who received prior systemic therapy. AVMAPKI FAKZYNJA CO-PACK is the fi. |
businesswire.com |
2025-05-08 17:17:00 |
Czytaj oryginał (ang.) |
| U.S. FDA approves Verastem's cancer therapy |
The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a type of ovarian cancer who have received prior treatment, the regulator said on Thursday. |
reuters.com |
2025-05-08 16:23:51 |
Czytaj oryginał (ang.) |
| Verastem Oncology to Present at Upcoming Investor Conferences |
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in May: H.C. Wainwright 3rd Annual BioConnect Investor Conference: Fireside chat on Tuesday, May 20 at 12:00 pm ET 2025 RBC Capital Markets Global Healthcare Conference: Fireside chat on Tuesday, May 20 at. |
businesswire.com |
2025-05-01 11:30:00 |
Czytaj oryginał (ang.) |
| Verastem Oncology Announces $75 million Private Placement |
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $24 million of shares of its common stock at a price of $7.00 per share and, in lieu of common stock to certain investors, $51 million of pre-funded warrants. |
businesswire.com |
2025-04-25 13:00:00 |
Czytaj oryginał (ang.) |
| Top Cancer Stocks to Buy to Boost Your Portfolio's Health |
If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics. |
zacks.com |
2025-04-16 14:46:10 |
Czytaj oryginał (ang.) |
| Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination |
Verastem, Inc.'s priority review PDUFA date of avutometinib + defactinib for treatment of patients with recurrent LGSOC is expected June 30th of 2025; At this time, no FDA advisory committee to be held. The global Non-small cell lung cancer market size is projected to reach $36.9 billion by 2031; KRAS G12C variant is the most common KRAS mutation, accounting for 13% of NSCLC cases. Data from phase 1/2 RAMP-203 study, using avutometinib + LUMAKRAS with or without defacinib to treat patients with KRAS G12C mutant NSCLC, is expected to be presented 2nd half of 2025. |
seekingalpha.com |
2025-04-10 18:35:24 |
Czytaj oryginał (ang.) |
| Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 164,500 shares of its common stock to fourteen new employees and the grant of 83,333 restricted stock units to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee's acceptance of employment with Verastem Oncology. |
businesswire.com |
2025-04-07 11:30:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade |
The average of price targets set by Wall Street analysts indicates a potential upside of 100.9% in Verastem (VSTM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-03-27 12:55:32 |
Czytaj oryginał (ang.) |
| Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025 |
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, announced today multiple oral and poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 to be held on April 25-30 in Chicago, Illinois. These presentations will highlight clinical and preclinical data from the Company's development programs, including VS-7375 (GFH375), an oral KRAS. |
businesswire.com |
2025-03-25 18:35:00 |
Czytaj oryginał (ang.) |
| Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates |
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months and full year ended December 31, 2024, and highlighted recent progress. “In 2024, we made tremendous progress across our pipeline programs, most notably the NDA acceptance of our novel-novel combination of avutometinib plus defactinib for Priority Review under the accelerated approval pathway f. |
businesswire.com |
2025-03-20 18:01:00 |
Czytaj oryginał (ang.) |
| Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference |
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025, at 1:00 pm EST. A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investors & Media section of the company's website at www.v. |
businesswire.com |
2025-01-29 09:30:00 |
Czytaj oryginał (ang.) |
| Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers |
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming catalysts for its novel clinical pipeline. "We ended 2024 having made tremendous progress across our pipeline programs, including FDA acceptance of our NDA with Priority Review for avutometinib plus defactinib in recurrent KRAS mutant low-grade serous ovarian cancer. As we h. |
businesswire.com |
2025-01-23 09:30:00 |
Czytaj oryginał (ang.) |
| Verastem Oncology Names Matthew E. Ros as Chief Operating Officer |
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Matthew E. Ros as chief operating officer. In his role, Mr. Ros will report to Dan Paterson, president and chief executive officer, and will serve on the company's executive leadership team. “We are thrilled to welcome Matt to Verastem Oncology at an important time as we prepare for a mid. |
businesswire.com |
2025-01-15 09:30:00 |
Czytaj oryginał (ang.) |
| Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 |
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced a new credit facility for up to $150 million along with an equity investment of $7.5 million with Oberland Capital Management LLC (Oberland Capital). In addition, the Company announced a strategic collaboration with IQVIA Inc. (IQVIA) to leverage IQVIA's world-class infrastructure and established commercial. |
businesswire.com |
2025-01-13 09:30:00 |
Czytaj oryginał (ang.) |
| Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 15,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee's acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have. |
businesswire.com |
2025-01-08 09:30:00 |
Czytaj oryginał (ang.) |
| Verastem: Planning The PDUFA Run-Up |
Verastem, Inc.'s NDA for avutometinib and defactinib in recurrent KRAS-mutant LGSOC has been accepted by the FDA, with a PDUFA date set for June 30, 2025. The combination therapy shows promising Phase II RAMP 201 results, with a 31% ORR and significant tumor size reduction, potentially positioning Verastem as a commercial-stage company by 2025. The LGSOC market is projected to reach $363.7M by 2034, with Verastem's therapy poised to capture a significant share due to the lack of approved treatments. |
seekingalpha.com |
2025-01-03 13:56:21 |
Czytaj oryginał (ang.) |
| Verastem: BLA Acceptance Puts Key Goals In Sight |
Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ovarian carcinoma. Financially, VSTM has limited cash reserves, with only 4-5 quarters of operating funds, posing a risk if there are approval delays. The market size for their therapy is uncertain, with potential revenues ranging from $85.7 million to $686 million annually. |
seekingalpha.com |
2025-01-02 13:39:30 |
Czytaj oryginał (ang.) |
| VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag |
The FDA accepts Verastem's NDA for the accelerated approval of avutometinib to treat recurrent KRAS mutant ovarian cancer under priority review. The stock rises 41%. |
zacks.com |
2025-01-02 13:07:26 |
Czytaj oryginał (ang.) |
| Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday? |
On Monday, the FDA accepted for review the New Drug Application under the accelerated approval pathway for Verastem Oncology's VSTM avutometinib. |
benzinga.com |
2024-12-31 12:59:23 |
Czytaj oryginał (ang.) |
| Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer |
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under the accelerated approval pathway for avutometinib, an oral RAF/MEK clamp, in combination with defactinib, an oral FAK inhibitor, for the treatment of adult patients with recurrent low-grade serous ovarian cancer (LGSOC), wh. |
businesswire.com |
2024-12-30 18:30:00 |
Czytaj oryginał (ang.) |
| Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer |
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced preliminary clinical data for the triplet combination of avutometinib and sotorasib plus defactinib in the RAMP 203 Phase 1/2 study in KRAS G12C mutant advanced non-small cell lung cancer (NSCLC). No dose-limiting toxicities (DLTs) have been observed in the triplet combination. RAMP 203 continues to progress, with additional enroll. |
businesswire.com |
2024-12-18 09:30:00 |
Czytaj oryginał (ang.) |
| Verastem: Preparing For Upcoming Catalysts |
Verastem's avutometinib and defactinib show promising clinical progress for recurrent KRAS-mutant LGSOC, with potential FDA approval and market launch by mid-2025. The company's strong cash position and strategic focus on RAS-driven cancers offer significant growth opportunities without imminent dilution risks. Upcoming catalysts include FDA filing decisions, interim data from NSCLC and pancreatic cancer trials, and potential commercial launch, driving Verastem's bullish outlook. |
seekingalpha.com |
2024-11-27 15:28:34 |
Czytaj oryginał (ang.) |
| Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference |
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3rd at 11:15 am EST. A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investors & Media section of the company's website at www.verastem.com. A repla. |
businesswire.com |
2024-11-26 09:00:00 |
Czytaj oryginał (ang.) |
| Verastem Oncology to Participate in Upcoming Investor Conferences |
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in the following upcoming investor conferences: 2024 Truist Securities BioPharma Symposium on November 7, 2024 Guggenheim Healthcare Innovation Conference; fireside chat on Wednesday, November 13, 2024 at 9:00 am EDT A live webcast of the fireside chat can be accessed under “Events & Pr. |
businesswire.com |
2024-10-31 09:30:00 |
Czytaj oryginał (ang.) |
| Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting |
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced updated data from the Phase 2 RAMP 201 (ENGOTov60/GOG3052) clinical trial evaluating the combination of avutometinib, an oral RAF/MEK clamp, and defactinib, an oral, selective FAK inhibitor, in patients with recurrent low-grade serous ovarian cancer (LGSOC). The data were published as a late-breaking abstract and additional detaile. |
businesswire.com |
2024-10-17 05:00:00 |
Czytaj oryginał (ang.) |
| Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting |
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced further details for its late-breaking presentation of mature data from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/GOG-3052) clinical trial to be presented as an oral presentation at a plenary session at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting taking place October 16-18, 2024 in Dublin, Ireland. The l. |
businesswire.com |
2024-10-09 10:00:00 |
Czytaj oryginał (ang.) |
| Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 109,000 shares of its common stock to nine new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options h. |
businesswire.com |
2024-10-07 11:30:00 |
Czytaj oryginał (ang.) |
| Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference |
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18 at 3:40 pm EDT. A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investors & Media section of the company's website at www.verastem.com. A replay of. |
businesswire.com |
2024-09-10 20:05:00 |
Czytaj oryginał (ang.) |
| Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity |
Verastem's Avutometinib and Defactinib combination therapy targets recurrent LGSOC and is expected to complete its rolling NDA by 2H2024. The company has a diverse pipeline, exploring treatments for metastatic pancreatic cancer and mKRAS G12C non-small cell lung cancer (NSCLC). Interim results for Avutometinib + Defactinib show a 45% ORR overall and 60% ORR for KRAS-mutant patients, with tumor regression in 86%. |
seekingalpha.com |
2024-09-06 03:21:59 |
Czytaj oryginał (ang.) |
| Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024 |
BOSTON & HOUSTON, Texas--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, and the STAAR Ovarian Cancer Foundation today announced the first Low-Grade Serous Ovarian Cancer Awareness Day or “LGSOC Awareness Day” on September 9, 2024. September is Ovarian Cancer Awareness Month and LGSOC is a rare ovarian cancer with little information and awareness available to patients and caregivers. This newly created. |
businesswire.com |
2024-09-03 11:30:00 |
Czytaj oryginał (ang.) |
| Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants |
BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants to purchase common stock in lieu of common stock for certain investors and accompanying warrants to purchase shares of common stock, in an underwritten public offering. The pre-f. |
businesswire.com |
2024-07-23 20:05:00 |
Czytaj oryginał (ang.) |
| Verastem (VSTM) Begins Dosing in Solid Tumors Study in China |
Verastem (VSTM) doses the first patient in a phase I/II study conducted by GenFleet Therapeutics, evaluating KRAS G12D inhibitor, GFH375/VS-7375 in solid tumors. Shares rise. |
zacks.com |
2024-07-15 16:46:16 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM |
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. ("Verastem" or the "Company") (NASDAQ:VSTM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-07-14 16:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM |
NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. (“Verastem” or the “Company”) (NASDAQ: VSTM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. |
globenewswire.com |
2024-07-12 19:17:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM |
NEW YORK , July 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. ("Verastem" or the "Company") (NASDAQ: VSTM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2024-07-10 23:28:00 |
Czytaj oryginał (ang.) |